Syntekabio Officially Launches ‘LM-VS’ SaaS Based on AI Language Model

Syntekabio, an AI drug development specialist company (CEO Jongseon Jeong), announced on the 20th that it will officially launch the AI language model-based Language Model Virtual Screening (hereinafter ‘LM-VS’) SaaS (Software as a Service).

‘LM-VS’ is an AI drug development platform meticulously developed by Syntekabio. By selecting one target protein and performing a single virtual screening, it can infinitely generate active compounds based on a compound library of over 13 billion compounds, 200 million protein structures predicted by Google AlphaFold, and all known 3D structural bank data to date.

Although 1,000 active compounds can be screened in one search, the company explains that it is common to run the screening at least 50 times, and even up to 100 or 200 times.

The main users are researchers involved in drug development, and since ‘LM-VS’ is cloud-based, users can access the service conveniently and quickly anytime and anywhere with internet access, regardless of location or time. In particular, the platform is modularized so that customers can use only the platforms they want, enhancing accessibility to the AI drug platform service. Currently, beyond the launched service modules, the company plans to sequentially phase modules to expand the service area throughout the entire drug development cycle.

Jongseon Jeong, CEO of Syntekabio, stated, “Since the first unveiling of ‘LM-VS’ at the JP Morgan Healthcare-Biotech Showcase held on the 13th, we plan extensive promotion in Korea, the United States, and several global countries. We expect this launched service to become a new paradigm in drug development.”

Syntekabio’s expectations for new launches of ‘LM-VS’ and L/O in the DDCS (DeepMatcher Drug Candidate Service) division are rising, and with the full-scale start of the colocation business, it is expected that sales will be secured in various business areas.